Eloralintide and retatrutide are experimental weight-management medicines with different hormone targets. Eloralintide acts through amylin signaling. Retatrutide activates receptors for GIP, GLP-1 and glucagon. Both have produced substantial weight loss in human trials, but the studies discussed here did not directly test one against the other.
That leaves a useful comparison to make, with a clear boundary. We can compare their mechanisms, the maturity of their research and the questions their trials answer. We cannot declare which would work better or cause fewer side effects for a particular person from separate placebo-controlled studies.
What each medicine is designed to do
Eloralintide, also called LY3841136, is a long-acting amylin receptor agonist. Amylin is involved in signals related to meals and fullness. An agonist activates a receptor, a place on a cell where a signal can act.
The early eloralintide discovery paper (https://pubmed.ncbi.nlm.nih.gov/41109426/) describes its receptor activity and initial human investigation. A selective target can be scientifically interesting without guaranteeing fewer symptoms. Human trials are needed to learn how the overall effect feels to people over time.
Retatrutide, also called LY3437943, is a single molecule acting at three receptor systems. GIP and GLP-1 are involved in responses to food and glucose regulation. Glucagon signaling adds another metabolic pathway. The drug is sometimes called reta online, but that nickname is not a separate medicine.
Lilly's explanation of retatrutide (https://www.lilly.com/news/stories/what-to-know-about-retatrutide) identifies it as investigational and describes the three targets. Counting targets does not rank treatments. Three pathways are not automatically three times the effect or three times the risk.
The eloralintide evidence in context
The 2025 phase 2 eloralintide trial (https://pubmed.ncbi.nlm.nih.gov/41207310/) studied 263 adults for 48 weeks. Reported efficacy-estimand average weight reductions across active regimens reached about 20%, compared with about 0.4% for placebo. It was a dose-finding study, with several relatively small treatment groups.
Phase 2 helps researchers decide whether an intervention is promising enough for larger trials and which regimens deserve investigation. It is an important step, although less informative about uncommon adverse effects than a much larger program. The tested population and analysis method must remain attached to the results.
The ENLIGHTEN-1 study description (https://next.trials.lilly.com/en-US/trial/664295) shows the larger phase 3 investigation under way. Planned research is useful context, but future outcomes should not be described as known. An experimental drug can enter phase 3 and still leave major benefit-and-risk questions unresolved.
Retatrutide has newer phase 3 results
The TRIUMPH-1 phase 3 report, published in September 2026 (https://www.nejm.org/doi/full/10.1056/NEJMoa2604169), randomized 2,339 adults with obesity without diabetes. Participants received retatrutide or placebo for 80 weeks. In the treatment-regimen analysis, average weight reductions were 17.6%, 23.7% and 25.0% across the tested groups, versus 3.9% with placebo.
This is a larger and longer trial than the earlier eloralintide study. It gives retatrutide a more mature evidence base for this particular population. It still does not supply a direct estimate of the difference between retatrutide and eloralintide, because eloralintide was not one of its treatment groups.
The trial also examined specified subgroups with knee osteoarthritis or obstructive sleep apnea. Findings about those conditions should be read with their own endpoints and participant numbers, rather than assumed to apply to everyone who lost weight.
Why 20% versus 25% is an incomplete comparison
Putting the largest averages side by side is tempting. One study ran for 48 weeks and the other for 80. Participants therefore had different amounts of time for their weight to change. A longer study can also reveal problems that a shorter study cannot observe.
The placebo groups differed too. That is a clue that the studies should not be treated as one shared experiment. Participant characteristics, background support, treatment schedules and analysis decisions can all affect the result. Subtracting percentages across separate trials does not remove those differences.
As an arithmetic illustration, a 20% reduction from 100 kg is 20 kg, while 25% is 25 kg. That explains percentages. It does not demonstrate that changing from one medicine to the other would cause an extra 5 kg of weight loss. No such switching experiment is contained in these results.
Why retatrutide headlines also mention 28.3%
The same trial can report more than one estimate because researchers ask more than one statistical question. Lilly's detailed TRIUMPH-1 results (https://www.lilly.com/hcp/medical-information/answers/what-are-the-results-of-retatrutide-from-triumph-1-in-participants-with-obesity-or-overweight-without-type-2-diabetes-386151) distinguish an efficacy analysis from a treatment-regimen analysis.
At the highest studied level, the efficacy analysis reported 28.3% average weight reduction, while the treatment-regimen analysis reported 25.0%. These figures handle events such as treatment discontinuation under different assumptions. Quoting the larger figure without explaining the analysis can leave readers with the wrong expectation.
For an everyday reader, the useful habit is to keep the analysis label beside the number. Ask whether the estimate describes effects under continued treatment assumptions or a broader treatment strategy that includes stopping. Neither estimate should be turned into a guaranteed personal outcome.
Which has fewer side effects?
The available trials cannot establish a clean tolerability ranking between these two medicines. Nausea and fatigue were common in the eloralintide phase 2 report. Retatrutide research has also reported gastrointestinal problems. The exact regimen, participant group and duration matter when reading a percentage.
A low side-effect rate in one small group can change when more people are studied. Conversely, a higher rate under one starting or escalation schedule does not necessarily describe every future regimen. Looking only at whether nausea occurred also misses how severe it was, how long it lasted and whether someone stopped treatment.
The most useful comparison would place both medicines in the same trial, use appropriate schedules and record symptoms in the same way. It would also track discontinuation, serious adverse events and daily functioning. Until then, describing one as the gentle option is an interpretation that the evidence cannot firmly support.
Weight loss, fat loss and muscle are different outcomes
A scale measures total weight. Body-composition studies try to separate components such as fat and lean tissue. Strength and physical function need additional measurements. None of those outcomes should be substituted for another just because a headline uses the phrase fat loss.
For example, a reader who wants to preserve strength needs evidence about strength or a closely relevant outcome. A promising animal result about fat mass cannot settle the human question. A larger weight reduction can be valuable for some people while still requiring attention to nutrition and physical function.
The practical discussion should begin with the person's goals and medical situation. Energy for daily activities, adequate food intake and symptom burden can matter alongside a weight percentage. Vegan foods such as tofu, beans and lentils offer protein options within a balanced eating plan, although they have not been shown here to alter either drug's trial results.
Eloralintide combinations are not retatrutide
Eloralintide is also being studied with tirzepatide, which targets GIP and GLP-1 receptors. Lilly's September 2026 EloraTZP report (https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide) concerns that combination in adults with type 2 diabetes.
Retatrutide is a different single molecule with a different combination of receptor activity. A result for eloralintide plus tirzepatide cannot be assigned to eloralintide alone, and cannot establish that eloralintide plus retatrutide would have the same balance of effects.
Online discussions sometimes use stacking as if combining agents simply adds their benefits. Interactions can also add uncertainty and adverse effects. The trials described here do not provide a personal protocol for mixing experimental products.
Approval and product quality
As of the research date in November 2026, the sources reviewed describe both medicines as investigational. Retatrutide has not become an approved retail treatment simply because phase 3 results have been published. Eloralintide's ongoing program likewise does not establish an approval date or routine availability.
The FDA's warning about unapproved weight-loss products (https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) specifically addresses retatrutide. It states that retatrutide cannot be used in compounding under US federal law. That is a US regulatory statement, not a claim about every country's rules.
A vial advertised on social media cannot be assumed to match the trial medicine. Identity, concentration, contamination and sterility are separate questions from whether a molecule works in a controlled study. Personal testimonials rarely establish any of those product details.
What Reddit experiences can contribute
Reader accounts can reveal concerns that a trial headline leaves unexplained: fatigue interfering with work, uncertainty about fullness, worries about weight regain or confusion over different analysis figures. These are worthwhile questions for patient-facing research.
The accounts remain unverified. People may use several substances, change their diet or receive products of uncertain identity. A favorable experience is not proof of superiority, and a difficult experience does not measure the frequency of that problem in all users. This article's separate reader-research notes keep those observations apart from clinical findings.
No reliable personal-use account is needed to make a mechanism comparison useful. A celebrity or clinician discussing a medicine online also does not establish that they take it, endorse a particular product or have tested it against another medicine.
What a fair future comparison would measure
A direct study would need comparable participants, adequate duration and a clear plan for handling discontinuation. It should measure benefits and harms using the same definitions in both groups. It would also need enough participants to make the differences reasonably precise.
For now, retatrutide has larger published phase 3 evidence, while eloralintide offers a different pathway with promising earlier efficacy findings and ongoing larger trials. The question of which medicine provides the better overall balance for a particular patient remains open. Readers can follow the research without turning cross-trial averages into a treatment choice.
30 Reddit comments: reader experiences and questions
These are paraphrases of 30 distinct public comments, collected on 20 November 2026. Each source link opens the original discussion. Usernames and relative dates are reproduced as displayed in the retrieved page; exact posting dates were not consistently available. These are unverified anecdotes and questions, not medical evidence or instructions. Some comments contain unsupported claims, multiple treatments or uncertain product identity. They are a qualitative sample, not a poll or an estimate of how often benefits or harms occur.
- HairPsychological617, displayed 1y ago: Claimed a positive eloralintide phase 2 trial experience.
- Thiccsmartie, displayed 1y ago: Asked what another commenter was using after trial participation.
- HairPsychological617, displayed 1y ago: Reported stopping a product described as reta after low blood pressure and poor sleep.
- Leading_Lunch_7571, displayed 1y ago: Interpreted eloralintide as promising alone compared with cagrilintide.
- Thiccsmartie, displayed 1y ago: Wanted to see results for eloralintide combined with tirzepatide.
- Perfect-Ad2578, displayed 1y ago: Compared several emerging medicines using separate trial headlines.
- xenobiotica_jon, displayed 1y ago: Expressed concern about very rapid weight loss while using multiple agents.
- Perfect-Ad2578, displayed 1y ago: Speculated about a practical limit to tolerable weight loss.
- Perfect-Ad2578, displayed 1y ago: Described slowing down a previous rapid-weight-loss routine after adverse experiences.
- Leading_Lunch_7571, displayed 1y ago: Asked how eloralintide differs from cagrilintide despite shared amylin activity.
- Thiccsmartie, displayed 1y ago: Inferred differences from separate trial percentages and molecular properties.
- Leading_Lunch_7571, displayed 1y ago: Discussed amylin and calcitonin receptor distinctions.
- Thiccsmartie, displayed 1y ago: Preferred receptor selectivity based on a personal interpretation.
- TracyIsMyDad, displayed 1y ago: Raised differences among amylin receptor subtypes.
- TracyIsMyDad, displayed 1y ago: Discussed lean mass versus total weight loss; the forum percentage is unverified here.
- Perfect-Ad2578, displayed 1y ago: Compared eloralintide and retatrutide averages from different trials.
- martapap, displayed 1y ago: Raised uncertainty about the identity of products sold outside regulated trials.
- Shafpocalypse, displayed 1y ago: Raised concern about nausea and vomiting in a discussion of emerging medicines.
- HairPsychological617, displayed 1y ago: Claimed eloralintide trial participation without nausea or vomiting.
- okiejay1, displayed 5mo ago: Suggested that another comment had confused eloralintide with amycretin.
- _Vlxd_, displayed 5mo ago: Reported appetite suppression during combined use with tirzepatide.
- _Vlxd_, displayed 5mo ago: Reported an evolving pattern of nausea and fullness over several days.
- HairPsychological617, displayed 5mo ago: Reported fatigue, constipation and perceived joint benefits.
- bjones54, displayed 5mo ago: Reported little early effect, illustrating variable personal experiences.
- Nenieeeee-977, displayed 1mo ago: Asked about an experimental add-on after a weight-loss plateau.
- NoMoreFatShame, displayed 12d ago: Reported food aversion during background treatment and major sleep disruption.
- AnotherToken, displayed 12d ago: Raised concern about lean mass on personal scans.
- Existing-Excuse9240, displayed 12d ago: Noted illness and dehydration as alternative explanations for rapid weight change.
- Hot-Lobster411, displayed 7d ago: Reported no clear effect early in a claimed blinded trial.
- Hot-Lobster411, displayed 7d ago: Prioritized knee-pain improvement over the amount of weight lost.
Author and editorial background
Bob Vaughan aka Healthy Mango has studied alternative medicine for around 30 years, with homeopathy certification obtained in India and certifications in yoga and Faster EFT. He has also studied Arthur Janov's Primal Therapy and received Primal Therapy at the Janov center in Los Angeles. These are owner-supplied biographical details, not medical credentials or evidence that a treatment works. Read the full author background.
Alternative & Complementary Medicine has published on these topics since January 2005, more than 20 years ago. Its original announcement records that history. This article links to research and explains its limits. AI assisted with research organization and drafting. No qualified medical review is claimed. Readers can send corrections through the contact page.




